Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Venatorx Pharmaceuticals develops anti-infectives to treat multi-drug-resistant bacterial infections and viral infections.
HilleVax is a biopharmaceutical company that focuses on the development and commercialization of novel vaccines.
Anjarium is focused on creating new class of non-viral gene therapies to deliver predictable ,inclusionary ways to tackle genetic diseases.
Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease.
Jasper Therapeutics is a biotechnology company that develops novel antibody therapies for stem cell transplants.
Scorpion Therapeutics is a clinical-stage oncology company that specializes in precision medicine for cancer patients.
Q32 Bio is a biotechnology company that develops treatments for patients with severe autoimmune and inflammatory diseases.
Entact Bio is a biotechnology company that is in the preclinical stages of developing medications to improve protein function.
Reneo Pharmaceuticals is an operator of a pharmaceutical company used to develop therapies for patients with orphan metabolic diseases.
cAMPfield Therapeutics is a biotechnology company that specializes on exploration and development activities of therapeutic solutions.
Antares is a biotechnology company focused on developing transformational,medicines targeting validated cancer and other serious diseases.
Spruce Biosciences is a biopharmaceutical company developing therapies for rare diseases that target the endocrine system.
Glycomine is an early-stage biotech working on replacement therapies for rare diseases.
Ascend Gene & Cell Therapies is a model for gene and cell therapy manufacturing.
R1 Therapeutics is a clinical-stage biopharmaceutical company that develops first-in-class treatments for kidney disease patients.
CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform.
Atsena Therapeutics is a clinical-stage gene therapy company that develops novel treatments for inherited forms of blindness.
Timberlyne Therapeutics is a biopharmaceutical company that develops therapies for autoimmune diseases.
Myricx Bio is a biotechnology company that develops novel NMT inhibitor payloads for ADCs to treat cancer.
Nido Biosciences is a clinical-stage company that develops precision medicines for severe neurological diseases.
Vaxcyte focuses on developing vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.
Vera Therapeutics is a biotechnology company developing innovative biologic therapeutics with transformative clinical potential.
Effector Therapeutics is an early-stage company focused on the discovery and development of small molecule cancer therapeutics.
Personalis is a contract research organization and genome-scale diagnostics services company specializing in genome guided medicine.
Abingworth has invested in 50 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Abingworth's top investment sectors include Biotechnology, Health Care, Therapeutics, Biopharma, Medical. The firm invests across 16 different industry categories.
Among tracked funding rounds, Vaxcyte received $632.5M in a Post-IPO Equity round. Abingworth's total known invested capital is $4.3B.
Abingworth's average investment size is $116.9M across its portfolio of 50 companies.
Recent Abingworth portfolio additions include Venatorx Pharmaceuticals, HilleVax, Anjarium Biosciences, Pathalys Pharma, Jasper Therapeutics. These companies were founded in 2020 or later.